AI Engines For more Details: Perplexity Kagi Labs You
Muscle Spasms: Chlorphenesin carbamate is primarily used to relieve muscle spasms. It works by blocking nerve impulses or pain sensations that are sent to the brain. This can help reduce muscle tightness and discomfort.
Muscle Strains: It may also be used to alleviate muscle strains, which occur when muscles are overstretched or torn. By relaxing the muscles, chlorphenesin carbamate can help reduce pain and stiffness associated with strains.
Topical Allergic Reactions: While uncommon, some individuals may experience allergic reactions to topical formulations containing chlorphenesin carbamate. Symptoms of an allergic reaction may include itching, redness, swelling, or rash at the application site.
Skin Irritation: In some cases, chlorphenesin carbamate can cause skin irritation or sensitivity at the application site. This may manifest as redness, burning, or stinging.
Respiratory Effects: Inhalation of chlorphenesin carbamate dust or vapors may irritate the respiratory tract and cause symptoms such as coughing, wheezing, or shortness of breath.
Eye Irritation: Contact with chlorphenesin carbamate may cause eye irritation. If the substance comes into contact with the eyes, individuals should flush the eyes with water and seek medical attention if irritation persists.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | 0 |
| Alzheimer's disease | 0.1 | 0.3 | -2 |
| Ankylosing spondylitis | 0.1 | 0.1 | 0 |
| Anorexia Nervosa | 0.1 | 0.1 | 0 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | 0 |
| Asthma | 0.3 | 0.1 | 2 |
| Atrial fibrillation | 0.1 | 0.1 | 0 |
| Autism | 0.1 | 0.2 | -1 |
| Autoimmune Disease | 0.1 | 0.1 | |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.1 | 0.1 | |
| Brain Trauma | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | -0.3 | |
| Carcinoma | 0.2 | 0.2 | |
| Celiac Disease | 0.1 | 0.1 | 0 |
| Cerebral Palsy | 0.1 | 0.1 | |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Kidney Disease | 0.1 | 0.1 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.1 | 2 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | 0 |
| Cognitive Function | 0.1 | 0.1 | 0 |
| Colorectal Cancer | 0.3 | 0.3 | |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 0.1 | 0.3 | -2 |
| Crohn's Disease | 0.2 | 0.2 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 0.4 | 0.4 | 0 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | 0.3 | -2 |
| Endometriosis | 0.1 | 0.1 | |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.1 | 0.1 | |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.1 | |
| gallstone disease (gsd) | 0.1 | 0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0.1 | 0.1 | 0 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.1 | 0.1 | |
| Graves' disease | 0.1 | -0.1 | |
| Gulf War Syndrome | 0.1 | 0.1 | |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 0.1 | -0.1 | |
| Heart Failure | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| hyperglycemia | 0.2 | 0.2 | |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.1 | 0.2 | -1 |
| IgA nephropathy (IgAN) | 0.1 | 0.1 | 0 |
| Inflammatory Bowel Disease | 0.3 | 0.3 | 0 |
| Insomnia | 0.3 | 0.1 | 2 |
| Irritable Bowel Syndrome | 0.1 | 0.1 | 0 |
| ischemic stroke | 0.1 | 0.1 | |
| Liver Cirrhosis | 0.4 | 0.2 | 1 |
| Long COVID | 0.1 | 0.1 | 0 |
| Lung Cancer | 0.1 | 0.1 | |
| Mast Cell Issues / mastitis | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.1 | 0.1 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.4 | 0.2 | 1 |
| Mood Disorders | 0.4 | 0.4 | 0 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 0.4 | 0.1 | 3 |
| myasthenia gravis | 0.1 | 0.1 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.1 | |
| Obesity | 0.2 | 0.6 | -2 |
| obsessive-compulsive disorder | 0.1 | 0.1 | 0 |
| Osteoarthritis | 0.1 | 0.1 | 0 |
| Osteoporosis | 0.1 | -0.1 | |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 0.4 | 0.1 | 3 |
| Polycystic ovary syndrome | 0.1 | 0.2 | -1 |
| primary biliary cholangitis | 0.1 | 0.1 | 0 |
| Primary sclerosing cholangitis | 0.1 | 0.1 | 0 |
| Psoriasis | 0.1 | 0.1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.2 | 0.2 | |
| Schizophrenia | 0.2 | 0.2 | |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Systemic Lupus Erythematosus | 0.2 | 0.2 | |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.2 | 0.1 | 1 |
| Type 2 Diabetes | 0.2 | 0.2 | 0 |
| Ulcerative colitis | 0.2 | 0.1 | 1 |
| Unhealthy Ageing | 0.2 | 0.2 | |
| Vitiligo | 0.1 | 0.1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
